Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1989 Jul;67(3):328–332.

The stimulation of IL-2 production by anti-rheumatic drugs.

J A Oben 1, G R Wallace 1, B M Chain 1, J C Foreman 1
PMCID: PMC1385348  PMID: 2668158

Abstract

IL-2 release from mouse splenocytes was measured by assaying the IL-2 on an IL-2-dependent cytotoxic T-lymphocyte line in culture (CTLL). Proliferation of the CTLL cells was monitored indirectly with the dye thiazolyl blue. The slow-acting anti-rheumatic drug auranofin at concentrations below 0.1 microM potentiated concanavalin A (Con A)-induced IL-2 release. Similar potentiation of Con A-induced IL-2 release was obtained with D-penicillamine, 1 microM-1 mM, and with the angiotensin-converting enzyme-inhibitor captopril, 10 nM-1 microM. Potentiation of Con A-induced IL-2 release was obtained with concentrations of the drugs likely to be achieved in vivo during therapy. Auranofin but not D-penicillamine and captopril inhibited Con A-induced IL-2 release at high concentrations (greater than 0.3 microM).

Full text

PDF
328

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blitstein-Willinger E. Normalization of defective interleukin 1 and interleukin 2 production in patients with pemphigus vulgaris following chrysotherapy. Clin Exp Immunol. 1985 Dec;62(3):705–714. [PMC free article] [PubMed] [Google Scholar]
  2. Blitstein-Willinger E., Streller A. In vitro effects of gold sodium thiomalate on IL-1, IL-2 production, IL-2 receptor expression and IL-2 responsiveness in thymocytes and peripheral blood mononuclear cells. Clin Exp Immunol. 1987 May;68(2):357–365. [PMC free article] [PubMed] [Google Scholar]
  3. Buchan G., Barrett K., Fujita T., Taniguchi T., Maini R., Feldmann M. Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. Clin Exp Immunol. 1988 Feb;71(2):295–301. [PMC free article] [PubMed] [Google Scholar]
  4. Butler M., Carruthers G., Harth M., Freeman D., Percy J., Rabenstein D. Pharmacokinetics of reduced D-penicillamine in patients with rheumatoid arthritis. Arthritis Rheum. 1982 Jan;25(1):111–116. doi: 10.1002/art.1780250120. [DOI] [PubMed] [Google Scholar]
  5. Combe B., Andary M., Klein B., Clot J., Sany J. Regulation of interleukin-2 production in rheumatoid arthritis. J Rheumatol. 1987 Apr;14(2):226–229. [PubMed] [Google Scholar]
  6. Combe B., Pope R. M., Fischbach M., Darnell B., Baron S., Talal N. Interleukin-2 in rheumatoid arthritis: production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. Clin Exp Immunol. 1985 Mar;59(3):520–528. [PMC free article] [PubMed] [Google Scholar]
  7. Dale M. M., Penfield A. Superoxide generation by either 1-oleoyl-2-acetylglycerol or A23187 in human neutrophils is enhanced by indomethacin. FEBS Lett. 1985 Jun 3;185(1):213–217. doi: 10.1016/0014-5793(85)80772-9. [DOI] [PubMed] [Google Scholar]
  8. Dimartino M. J., Walz D. T. Inhibition of lysosomal enzyme release from rat leukocytes by auranofin. A new chrysotherapeutic agent. Inflammation. 1977 Jun;2(2):131–142. doi: 10.1007/BF00918675. [DOI] [PubMed] [Google Scholar]
  9. Farrar J. J., Benjamin W. R., Hilfiker M. L., Howard M., Farrar W. L., Fuller-Farrar J. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunol Rev. 1982;63:129–166. doi: 10.1111/j.1600-065x.1982.tb00414.x. [DOI] [PubMed] [Google Scholar]
  10. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  11. Gomez-Reino J., Miller F., Meiselas L. In vitro response of peripheral blood lymphocytes from patients with rheumatoid arthritis to lipopolysaccharides. J Lab Clin Med. 1980 Mar;95(3):335–342. [PubMed] [Google Scholar]
  12. Griswold D. E., Lee J. C., Poste G., Hanna N. Modulation of macrophage-lymphocyte interactions by the antiarthritic gold compound, auranofin. J Rheumatol. 1985 Jun;12(3):490–497. [PubMed] [Google Scholar]
  13. Hamburger M. I., Lawley T. J., Kimberly R. P., Plotz P. H., Frank M. M. A serial study of splenic reticuloendothelial system Fc receptor functional activity in systemic lupus erythematosus. Arthritis Rheum. 1982 Jan;25(1):48–54. doi: 10.1002/art.1780250108. [DOI] [PubMed] [Google Scholar]
  14. Haskard D. O., Currey H. L. Gold exacerbates adjuvant arthritis in the rat. Ann Rheum Dis. 1984 Apr;43(2):350–351. doi: 10.1136/ard.43.2.350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hurst N. P., Nuki G. Evidence for defect of complement-mediated phagocytosis by monocytes from patients with rheumatoid arthritis and cutaneous vasculitis. Br Med J (Clin Res Ed) 1981 Jun 27;282(6282):2081–2083. doi: 10.1136/bmj.282.6282.2081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Huskisson E. C., Scott J., Balme H. W., Dieppe P. A., Trapnell J., Willoughby D. A. Immunostimulant therapy with levamisole for rheumatoid arthritis. Lancet. 1976 Feb 21;1(7956):393–395. doi: 10.1016/s0140-6736(76)90218-x. [DOI] [PubMed] [Google Scholar]
  17. Kitas G. D., Salmon M., Farr M., Gaston J. S., Bacon P. A. Deficient interleukin 2 production in rheumatoid arthritis: association with active disease and systemic complications. Clin Exp Immunol. 1988 Aug;73(2):242–249. [PMC free article] [PubMed] [Google Scholar]
  18. Kunkel S. L., Chensue S. W., Phan S. H. Prostaglandins as endogenous mediators of interleukin 1 production. J Immunol. 1986 Jan;136(1):186–192. [PubMed] [Google Scholar]
  19. Lipsky P. E., Ziff M. Inhibition of antigen- and mitogen-induced human lymphocyte proliferation by gold compounds. J Clin Invest. 1977 Mar;59(3):455–466. doi: 10.1172/JCI108660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lotz M., Tsoukas C. D., Robinson C. A., Dinarello C. A., Carson D. A., Vaughan J. H. Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies. J Clin Invest. 1986 Sep;78(3):713–721. doi: 10.1172/JCI112631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Martin M. F., Surrall K. E., McKenna F., Dixon J. S., Bird H. A., Wright V. Captopril: a new treatment for rheumatoid arthritis? Lancet. 1984 Jun 16;1(8390):1325–1328. doi: 10.1016/s0140-6736(84)91821-x. [DOI] [PubMed] [Google Scholar]
  22. Merryman P., Jaffee I. A. Effect of penicillamine on the proliferative response of human lymphocytes. Proc Soc Exp Biol Med. 1978 Jan;157(1):155–158. doi: 10.3181/00379727-157-40011. [DOI] [PubMed] [Google Scholar]
  23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  24. Nakamura H., Igarashi M. Localization of gold in synovial membrane of rheumatoid arthritis treated with sodium aurothiomalate. Studies by electron microscope and electron probe x-ray microanalysis. Ann Rheum Dis. 1977 Jun;36(3):209–215. doi: 10.1136/ard.36.3.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Oben J. A., Foreman J. C. Stimulatory effects of anti-rheumatic drugs on human neutrophil functions. Immunopharmacology. 1988 Nov-Dec;16(3):157–165. doi: 10.1016/0162-3109(88)90004-5. [DOI] [PubMed] [Google Scholar]
  26. Panayi G. S. Response of rheumatoid-synovial-fluid lymphocytes to non-specific mitogens. Lancet. 1973 Sep 1;2(7827):512–513. doi: 10.1016/s0140-6736(73)92121-1. [DOI] [PubMed] [Google Scholar]
  27. Rabin H., Hopkins R. F., 3rd, Ruscetti F. W., Neubauer R. H., Brown R. L., Kawakami T. G. Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells. J Immunol. 1981 Nov;127(5):1852–1856. [PubMed] [Google Scholar]
  28. Rappaport R. S., Dodge G. R. Prostaglandin E inhibits the production of human interleukin 2. J Exp Med. 1982 Mar 1;155(3):943–948. doi: 10.1084/jem.155.3.943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Silverman H. A., Johnson J. S., Vaughan J. H., McGlamory J. C. Altered lymphocyte reactivity in rheumatoid arthritis. Arthritis Rheum. 1976 May-Jun;19(3):509–515. doi: 10.1002/art.1780190301. [DOI] [PubMed] [Google Scholar]
  30. Stratton J. A., Peter J. B. The responses of peripheral blood and synovial fluid lymphocytes of patients with rheumatoid arthritis to in vitro stimulation with mitogens. Clin Immunol Immunopathol. 1978 Jun;10(2):233–241. doi: 10.1016/0090-1229(78)90031-4. [DOI] [PubMed] [Google Scholar]
  31. Tada H., Shiho O., Kuroshima K., Koyama M., Tsukamoto K. An improved colorimetric assay for interleukin 2. J Immunol Methods. 1986 Nov 6;93(2):157–165. doi: 10.1016/0022-1759(86)90183-3. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES